^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    cevostamab (RG6160)

    i
    Other names: RG6160, BFCR 4350A, RG 6160, BFCR4350A, RO-7187797, RO7187797, BFCR-4350A, RG-6160, RO 7187797
    Associations

    News

    Trials
    Company:
    Roche
    Drug class:
    CD3 agonist, FCRH5 inhibitor
    Related drugs:
    Associations

    News

    Trials
    5d
    Emerging T-Cell Engagers and Novel Immunotargets in Multiple Myeloma. (PubMed, Oncology (Williston Park))
    T cell-redirecting therapies represent a central pillar in modern oncology, delivering high response rates across hematologic malignancies with expanding roles in earlier treatment settings. Future progress will depend on improving durability, optimizing sequencing, mitigating toxicity, and enhancing real-world deliverability through next-generation and multitarget platforms.
    Review • Journal
    |
    DLL3 (Delta Like Canonical Notch Ligand 3)
    |
    Yescarta (axicabtagene ciloleucel) • Breyanzi (lisocabtagene maraleucel) • Kymriah (tisagenlecleucel-T) • Epkinly (epcoritamab-bysp) • Elrexfio (elranatamab-bcmm) • Imdelltra (tarlatamab-dlle) • Tecartus (brexucabtagene autoleucel) • Talvey (talquetamab-tgvs) • Tecvayli (teclistamab-cqyv) • Columvi (glofitamab-gxbm) • cevostamab (RG6160)
    21d
    To Evaluate the Effects of Cevostamab in Participants With Systemic Lupus Erythematosus With or Without Active Lupus Nephritis (clinicaltrials.gov)
    P1, N=46, Not yet recruiting, Genentech, Inc.
    New P1 trial
    |
    Actemra IV (tocilizumab) • cevostamab (RG6160)
    1m
    CEVOLUTION: Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma (clinicaltrials.gov)
    P3, N=380, Recruiting, Hoffmann-La Roche | Not yet recruiting --> Recruiting | Trial primary completion date: Jun 2029 --> Oct 2028
    Enrollment open • Trial primary completion date
    |
    carfilzomib • dexamethasone • pomalidomide • Empliciti (elotuzumab) • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • cevostamab (RG6160)
    1m
    GA46280: Clinical Study to Evaluate the Effects of Cevostamab in Patients with Lupus with or without Active Lupus Nephritis (2025-522904-26-00)
    P1, N=17, Not yet recruiting, Genentech Inc. | N=10 --> 17
    Enrollment change
    |
    cevostamab (RG6160)
    2ms
    CEVOLUTION: Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma (clinicaltrials.gov)
    P3, N=380, Not yet recruiting, Hoffmann-La Roche
    New P3 trial
    |
    carfilzomib • dexamethasone • pomalidomide • Empliciti (elotuzumab) • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • cevostamab (RG6160)
    2ms
    GA46280: Clinical Study to Evaluate the Effects of Cevostamab in Patients with Lupus with or without Active Lupus Nephritis (2025-522904-26-00)
    P1, N=10, Not yet recruiting, Genentech Inc.
    New P1 trial
    |
    cevostamab (RG6160)
    4ms
    A Study Evaluating the Pharmacokinetics, Safety, and Efficacy of Cevostamab in Chinese Participants With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=20, Recruiting, Hoffmann-La Roche | Trial completion date: May 2028 --> Nov 2028 | Trial primary completion date: May 2028 --> Nov 2028
    Trial completion date • Trial primary completion date
    |
    Actemra IV (tocilizumab) • cevostamab (RG6160)
    5ms
    GO39775: Dose-Escalation Study of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM) (clinicaltrials.gov)
    P1, N=355, Completed, Genentech, Inc. | Active, not recruiting --> Completed | Trial completion date: Apr 2026 --> Jan 2026 | Trial primary completion date: Apr 2026 --> Jan 2026
    Trial completion • Trial completion date • Trial primary completion date
    |
    Actemra IV (tocilizumab) • cevostamab (RG6160)
    6ms
    CAMMA 1: A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=126, Active, not recruiting, Genentech, Inc. | Trial primary completion date: Dec 2025 --> Dec 2029 | Trial completion date: Dec 2025 --> Dec 2029
    Trial completion date • Trial primary completion date
    |
    Darzalex (daratumumab) • dexamethasone • pomalidomide • Actemra IV (tocilizumab) • cevostamab (RG6160)
    6ms
    Cevostamab Following CAR T Cell Therapy for RRMM (clinicaltrials.gov)
    P2, N=30, Active, not recruiting, University of Pennsylvania | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    cevostamab (RG6160)
    10ms
    PLYCOM: A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple Myeloma (clinicaltrials.gov)
    P1/2, N=200, Recruiting, Hoffmann-La Roche | Trial completion date: May 2027 --> Jul 2028 | Trial primary completion date: May 2027 --> Jul 2028
    Trial completion date • Trial primary completion date
    |
    lenalidomide • dexamethasone • Actemra IV (tocilizumab) • iberdomide (CC-220) • cevostamab (RG6160)
    10ms
    A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM) (clinicaltrials.gov)
    P1, N=120, Recruiting, Genentech, Inc. | Trial completion date: Jul 2026 --> Jul 2027 | Trial primary completion date: Jul 2026 --> Jul 2027
    Trial completion date • Trial primary completion date
    |
    Elrexfio (elranatamab-bcmm) • Actemra IV (tocilizumab) • cevostamab (RG6160)